Initial studies with rodent models indicated that GLP-1 is highly effective as an insulinotropic agent in non-diabetic, metabolically healthy animals, but shared substantially reduced biological activity in diabetic animals with the previously identified incretin glucose-dependent insulinotropic polypeptide (GIP) [4]
They are not FDA approved and have not been evaluated for safety, effectiveness, or quality by the FDA
That version of the drug has been sold as the once-daily pill Rybelsus by Novo Nordisk, which also makes the GLP-1 drugs Ozempic and Wegovy
These warrant prompt provider contact and possible gastroenterology referral
Even if there is a link with depression and suicidal behavior, its rare that people taking GLP-1 drugs experience these serious side effects
The Role of PYY in pancreatic islet physiology and surgical control of diabetes